乙型肝炎感染的管理

StephenW

Management of Hepatitis B Infection
Source: Clinical Resources From inPractice Hepatology
Stefan Zeuzem, MD
Program Director
Harry L. A. Janssen, MD, PhD
Milan J. Sonneveld, MD, PhD, MSc
Released: June 17, 2019
Back Next
Introduction

Chronic HBV infection affects an estimated 257 million people globally, with the majority of infected patients residing in southeast Asia and sub-Saharan Africa.[1] High rates of chronic HBV infection are also found in the Amazon as well as southeast and central Europe, whereas lower rates (< 1%) are found in western Europe and North America. Prolonged infection with HBV may result in progression of liver disease from necroinflammation to fibrosis and cirrhosis and may also lead to the development of hepatocellular carcinoma and result in early death.[2] Successful anti-HBV therapy may reduce the probability of disease progression, and treatment guidelines from the American Association for the Study of Liver Diseases (AASLD)[3] and the European Association for the Study of the Liver (EASL)[4] therefore recommend treatment of chronic HBV infection in patients with persistent necroinflammation and viral replication. Current treatment guidelines recommend certain nucleos(t)ide analogues or peginterferon as first-line therapy options for treating chronic HBV infection. This module focuses on the appropriate management strategy for HBV-infected patients, as well as on how to modify treatment in the case of suboptimal response.
乙型肝炎感染的管理
资料来源：实践肝病学的临床资源
Stefan Zeuzem，医学博士
方案主任
Harry L. A. Janssen，医学博士，博士
Milan J. Sonneveld，医学博士，博士，理学硕士
发行日期：2019年6月17日
上一页下一页
介绍

慢性HBV感染影响全球约2.57亿人，大多数感染患者居住在东南亚和撒哈拉以南非洲。[1]在亚马逊以及东南欧和中欧也发现了高比率的慢性HBV感染率，这种较低的比率（<1％）存在于西欧和北美。长期感染HBV可能导致肝病从坏死性炎症进展为纤维化和肝硬化，并且还可能导致肝细胞癌的发展并导致早期死亡。 [2]成功的抗HBV治疗可以降低疾病进展的可能性，以及美国肝病研究协会（AASLD）[3]和欧洲肝脏研究协会（EASL）的治疗指南[4] ]]建议推荐治疗持续性坏死性炎症和病毒复制的慢性HBV感染。目前的治疗指南建议某些核苷（酸）类似物作为聚乙二醇干扰素作为治疗慢性HBV感染的一线治疗方案。该模块侧重于HBV感染患者的适当管理策略，以及如何在次优应答的情况下修改治疗。

https://www.clinicaloptions.com/ ... v-management/page-1